Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology.
“That encouraging response rate is about twice the rate produced by PD1 checkpoint inhibitors in previous clinical trials,...
MD Anderson hosts Biden Cancer Community Summit
The University of Texas MD Anderson Cancer Center today joined with more than 450 communities and institutions across the country in hosting...
MD Anderson immunotherapy expert Sharma wins Coley Award
Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at The University of Texas MD Anderson...
Study links BAP1 protein to tumor suppression in kidney, eye, bile duct and mesothelioma cancers
Researchers at The University of Texas MD Anderson Cancer Center have shown how BRCA-associated protein 1 (BAP1) serves as a tumor suppressor gene in kidney, eye, bile duct, mesothelioma and other cancers by regulating a form of cell death called ferroptosis, opening up a potential new area of therapy research. Findings from the study, led by Boyi Gan, Ph.D., associate professor of Experimental Radiation Oncology, were published...
